Sage Therapeutics, Inc. (SAGE)
Chart Events
Performance Outlook
| Previous Close | 32.22 |
| Open | 32.87 |
| Bid | 34.25 x 800 |
| Ask | 34.30 x 1400 |
| Day's Range | 32.33 - 34.48 |
| 52 Week Range | 27.36 - 79.45 |
| Volume | |
| Avg. Volume | 692,488 |
| Market Cap | 2.013B |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | 3.09 |
| EPS (TTM) | 11.06 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.14 |
- Business Wire
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 04, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 8:00am PT (11:00am ET) in Las Vegas, Nev.
- Zacks
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass., May 03, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2022.
